XORTX Therapeutics Inc. Stock price

Equities

XRTX

CA98420Q3061

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:46:22 2024-03-27 pm EDT 5-day change 1st Jan Change
4.875 CAD -4.79% Intraday chart for XORTX Therapeutics Inc. -15.22% +68.10%
Sales 2023 * - Sales 2024 * - Capitalization 14.13M 19.22M
Net income 2023 * -8M -10.88M Net income 2024 * - EV / Sales 2023 * -
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * -
P/E ratio 2023 *
-1.2 x
P/E ratio 2024 *
-
Employees 3
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.05%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.79%
1 week-15.22%
Current month+18.90%
1 month+28.29%
3 months+68.69%
6 months-35.52%
Current year+68.10%
More quotes
1 week
4.57
Extreme 4.57
6.50
1 month
4.00
Extreme 4
9.35
Current year
2.90
Extreme 2.9
9.35
1 year
2.65
Extreme 2.65
10.62
3 years
2.65
Extreme 2.65
89.81
5 years
2.65
Extreme 2.65
89.81
10 years
2.65
Extreme 2.65
89.81
More quotes
Managers TitleAgeSince
Founder 64 18-01-08
Director of Finance/CFO 65 18-11-05
Chief Tech/Sci/R&D Officer - 21-06-30
Members of the board TitleAgeSince
Director/Board Member - 18-01-24
Founder 64 18-01-08
Chairman 67 22-06-05
More insiders
Date Price Change Volume
24-03-27 4.875 -4.79% 7,704
24-03-26 5.12 -1.54% 8,183
24-03-25 5.2 -11.86% 13,594
24-03-22 5.9 -9.09% 36,625
24-03-21 6.49 +12.87% 66,873

Delayed Quote Toronto S.E., March 27, 2024 at 03:46 pm EDT

More quotes
XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
4.875
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock XORTX Therapeutics Inc. - Toronto S.E.